Compare Ascendis Pharma A/S (ASND) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $28.06. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals.
| ASND | FNGU | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $36.15 |
52-Week Low | $163.32 | $13.73 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
FNGU trades at $28.64, up 0.77% on the day, with technical indicators showing a bullish trend from moving averages but caution from oscillators like the 6-day RSI at 95.66. Recent news highlights extreme volatility, with a 16% single-session drop reported on June 5, 2026, underscoring the leveraged ETN's high-risk nature. The asset lacks traditional fundamental metrics like P/E or revenue data, as it is an exchange-traded note tracking the FANG+ Index with 3x leverage.
The outlook for FNGU is highly speculative, driven by momentum in tech stocks but fraught with decay risks from daily rebalancing. Opportunities exist for short-term traders betting on Nasdaq-100 rallies, while risks include rapid capital erosion during market downturns, as evidenced by recent losses. Investors must understand the product's structure to avoid unintended losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
